Defining co-related parameters between 'metabolic' flare and 'clinical', 'biochemical', and 'osteoblastic' flare and establishing guidelines for assessing response to treatment in cancer.
Basu
Sandip
S
Alavi
Abass
A
D000970:Antineoplastic Agents / Q000009:adverse effects*; D016477:Artifacts; D019788:Fluorodeoxyglucose F18 / Q000008:administration & dosage / Q000493:pharmacokinetics; D006801:Humans; D007249:Inflammation / Q000000981:diagnostic imaging* / Q000209:etiology*; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000628:therapy; D010006:Osteoblasts / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism / Q000528:radiation effects; D049268:Positron-Emission Tomography / Q000379:methods; D017410:Practice Guidelines as Topic; D011379:Prognosis; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000493:pharmacokinetics; D011878:Radiotherapy / Q000009:adverse effects*; D013997:Time Factors; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18